Ipsen net worth in 2024 reflects its position as a major player in the biopharmaceutical industry.
With a market cap of $10.20 billion, Ipsen continues to thrive, driven by its focus on oncology and neuroscience.
In this analysis, Ando Money explores Ipsen’s financial growth, product performance, and future outlook, providing readers with the most up-to-date information on the company’s finances.
Quick Facts
| FACT | DETAIL |
|---|---|
| Name | Ipsen |
| Full Name | Ipsen S.A. |
| Website | ipsen.com |
| Industry | Biopharmaceuticals |
| Traded as | Euronext Paris: IPN, ADR: IPSEY |
| ISIN | FR0010259150 |
| Founded | 1929 |
| Founders | Henri Beaufour |
| Country/Territory | France |
| Headquarters | Paris, France |
| Chief Executive Officer | David Loew |
| Number of Employees | 5,700 |
| Market Cap | $10.20 billion |
| Total Assets | €6,547.2 million ($6.87 billion) |
| Total Equity | €4,046.1 million ($4.24 billion) |
| Revenue | €1,751.8 million ($1.84 billion) |
| Net Income | €232.3 million ($243 million) |
What is the Net Worth/Market Cap of Ipsen in 2024?
Ipsen’s market cap in 2024 stands at $10.20 billion, positioning it as a globally recognized biopharmaceutical company. This value highlights its growth and resilience, particularly in the fields of oncology and neuroscience.
Comparatively, Ipsen is on par with many global competitors, although it might not rival the largest pharmaceutical giants. Below are some related companies in the industry:
- Pfizer
- Novartis
- Merck & Co.
- Bristol-Myers Squibb
- Sanofi
- Roche
- AbbVie
- Amgen
- Eli Lilly
- GSK
You can also explore companies at the top of the financial game by checking out the biggest financial players.
Ipsen Financial Performance Overview
Recent Revenue Trends and Year-over-Year Growth
Ipsen‘s revenue growth has been impressive in recent years. For the first half of 2024, total sales reached €1,659.3 million ($1.74 billion), an 8.0% increase compared to 2023, with 9.5% growth at constant exchange rates.
This solid performance is mainly driven by its oncology and neuroscience portfolios. Additionally, the growth reflects new product launches and strengthened global presence.
Main Factors Influencing Revenue Growth in 2024
Ipsen’s oncology segment plays a critical role in its revenue increase. Products such as Cabometyx® and Onivyde® continue to perform well, contributing to the company’s expansion.
Ipsen also saw gains from the neuroscience segment, particularly from Dysport®, which showed a 9.2% growth.
Furthermore, Ipsen’s acquisition of products like Bylvay® significantly boosted its rare disease sales.
Performance of Oncology Products
Key oncology products like Somatuline® generated €522.2 million ($547.7 million), while Cabometyx® brought in €304.2 million ($318.9 million), reflecting 14.5% growth.
Additionally, Onivyde®, primarily used in treating pancreatic cancer, saw a 25.3% increase in revenue to €97.2 million ($102 million).
These products remain essential to Ipsen’s growth.
Neuroscience Contributions
In the neuroscience segment, Dysport®, a widely recognized treatment for both aesthetic and therapeutic purposes, generated €348.7 million ($365.6 million), a 9.2% increase compared to 2023.
Ipsen has continued to expand Dysport’s reach into new territories and therapeutic indications, boosting overall sales.
Geographic Breakdown of Ipsen’s Sales
Ipsen’s performance varies across regions, with the North American market contributing €541.9 million ($568.4 million) in sales, a 10.2% increase.
The European market also saw growth, with total sales reaching €647.6 million ($679.2 million).
In the Rest of the World, Ipsen experienced a 10.2% increase, generating €469.8 million ($492.4 million).
Contributions from Partnered Products and Licensing
Products developed in collaboration with other firms, such as Onivyde® and Tazverik®, have also contributed to Ipsen’s financial health.
The licensing agreements around these products allowed Ipsen to access broader markets and grow its sales base, particularly in North America.
R&D Spending and Its Impact on Financial Performance
In 2024, Ipsen continued to invest heavily in research and development, spending €323.4 million ($339 million), reflecting a 19.5% of total sales.
This investment has led to the expansion of Ipsen’s product pipeline, with new drugs in the oncology and rare disease segments.
Notably, the launch of Iqirvo® and advances in next-generation neurotoxins have enhanced Ipsen’s growth prospects.
Core Operating Income vs IFRS Operating Income
Ipsen’s core operating income reached €538.0 million ($563.6 million) in H1 2024, a 2.8% increase.
However, the IFRS operating income remained stable at €317.8 million ($332.7 million).
The difference is mainly due to higher R&D expenses and restructuring costs.
Free Cash Flow and Debt Position
Free cash flow improved by 5.9%, totaling €393.5 million ($412.3 million).
Ipsen’s closing net debt for H1 2024 was significantly reduced to €6.8 million ($7.1 million), a clear improvement from the prior year’s €272.2 million ($285 million).
This healthy financial position reflects efficient cash flow management and cost controls.
Financial Outlook for the Full Year
For 2024, Ipsen has upgraded its financial guidance, with total sales expected to grow by 7.0% at constant exchange rates.
The launch of new products, such as Iqirvo®, and increased global penetration for existing products like Cabometyx®, should help maintain this upward trajectory.
FAQs about Ipsen
What are the key products driving Ipsen’s growth?
Its growth is primarily driven by its oncology products like Cabometyx®, Onivyde®, and Somatuline®, along with the neuroscience product Dysport®.
How much does Ipsen invest in research and development?
It invested €323.4 million ($339 million) in research and development in the first half of 2024, which accounted for 19.5% of total sales.
What is Ipsen’s free cash flow in 2024?
It generated €393.5 million ($412.3 million) in free cash flow in H1 2024, reflecting a 5.9% increase from the previous year.
What was Ipsen’s core operating income in 2024?
Its core operating income for H1 2024 was €538.0 million ($563.6 million), a 2.8% increase compared to 2023.
How is Ipsen performing in North America?
In H1 2024, Ipsen achieved €541.9 million ($568.4 million) in sales from North America, representing a 10.2% growth year-over-year.
Conclusion
Ipsen’s financial performance in 2024 demonstrates strong growth across its product portfolio and regions.
For more insights into top companies and their financials, explore Ando Money’s content on our website. Feel free to leave comments or share this article!
